Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of meropenem tablets in China. Welcome to wholesale bulk high quality meropenem tablets for sale here from our factory. Good service and reasonable price are available.
Meropenem Tablets covalently bind with penicillin binding proteins (PBPs) to inhibit bacterial cell wall peptidoglycan cross-linking; Pyrrolidine sulfide side chains can enhance the stability of renal dehydropeptidase-I (DHP-I) without the need for combined enzyme inhibitors such as cilastatin; 1-Hydroxyethyl endows stability to various β - lactams, including AmpC enzymes. Therefore, it can exert bactericidal effects through a dual mechanism, binding to PBPs (especially PBP2), blocking the cross-linking of peptidoglycan chains, leading to bacterial cell wall defects; Its molecular polarity is low, making it easy to penetrate Gram negative bacterial outer membrane porins (such as OmpF/OmpC) and reach high concentrations within the bacterial body.
Our products
Additional information of chemical compound:
|
|
|
Meropenem COA
adverse reaction
Meropenem(Meropenem Tablets), as a fourth generation carbapenem antibiotic, is the core drug for the clinical treatment of severe Gram negative bacterial infections through its injectable powder injection. Although its nephrotoxicity and central nervous system toxicity are significantly reduced compared to imipenem, adverse reactions still require systematic understanding.
Adverse reaction spectrum and incidence rate :Common adverse reactions (incidence rate ≥ 1%)
Nausea/vomiting: The incidence rate is about 3.6% -4.8%, which is related to the drug directly stimulating the gastric mucosa and the vomiting reflex mediated by the central nervous system (CNS).
Diarrhea: The incidence rate is 2.1% -4.5%, including functional diarrhea (1.8%) and antibiotic associated diarrhea (AAD, 0.3% -0.7%), the latter of which may be caused by overgrowth of Clostridium difficile.
Constipation: The incidence rate is about 1.2%, which may be related to increased water absorption caused by dysbiosis of the gut microbiota.
Neurological symptoms
Headache: The incidence rate is 2.3% -3.1%, which may be related to an increase in prostaglandin synthesis after crossing the blood-brain barrier.
Epilepsy: The overall incidence rate is 0.5%, but the risk is significantly increased in specific populations
CNS infection (such as meningitis) patients: incidence rate increases to 2.1% -3.4%;Patients with renal insufficiency (CrCL<30mL/min) have a 2.3-fold increased risk;Patients who use valproic acid in combination have a 5-8 fold increased risk of epilepsy (due to Meropenem reducing blood concentration of valproic acid).
Rash: The incidence rate is 1.5% -2.7%, mostly maculopapular, which can disappear on its own after discontinuation of medication.
Itching: The incidence rate is 0.9% -1.2%, which may be related to histamine release.
Hematological abnormalities
Anemia: incidence rate of 0.7% -1.1%, manifested as a decrease in hemoglobin of ≥ 2g/dL, which may be related to drug-induced immune hemolysis or bone marrow suppression.
Thrombocytopenia: incidence rate of 0.3% -0.5%, mostly mild (PLT<100 × 10 ⁹/L), can be recovered after discontinuation of medication.
1.Allergic reaction
Allergic shock: The incidence rate is about 0.05%, mostly occurring within 30 minutes after administration, manifested as hypotension, difficulty breathing, and loss of consciousness.
DRESS syndrome (drug response with eosinophilia and systemic symptoms): incidence<0.01%, but mortality rate as high as 10%, characterized by fever, rash, lymphadenopathy, and multiple organ involvement.
2.Severe skin reaction
Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have an incidence rate of approximately 0.01% -0.03% and a mortality rate of 30%, requiring immediate discontinuation of medication and supportive treatment.
3.Hepatotoxicity
Cholestasis jaundice: incidence rate<0.1%, manifested as elevated ALT/AST (>3 times ULN) accompanied by elevated alkaline phosphatase (ALP), which is often reversible after discontinuation of medication.
4.Hematological suppression
Neutropenia: incidence rate of 0.05% -0.1%, more common in patients with long-term medication (>14 days) or concomitant chemotherapy.
Mechanism of adverse reactions
Microbial mechanism of antibiotic associated diarrhea
Colonization of Clostridium difficile: Meropenem can inhibit the normal gut microbiota (such as Bifidobacterium and Lactobacillus), leading to overgrowth of Clostridium difficile. The toxins A/B produced by Meropenem break down the intestinal mucosal barrier, causing pseudomembranous colitis.
Reduced short chain fatty acids (SCFAs): SCFAs such as butyric acid produced by normal microbial metabolism have anti-inflammatory and maintenance effects on intestinal mucosal integrity, and their reduction can exacerbate intestinal inflammation.
Molecular mechanism of epileptic seizures
Inhibition of gamma aminobutyric acid (GABA) receptors: Meropenem Tablets can penetrate the blood-brain barrier and competitively bind to GABA receptor binding sites, reducing the efficacy of the inhibitory neurotransmitter GABA and leading to neuronal overexcitation.
Increased release of glutamate: By inhibiting the glutamate transporter EAAT2 in astrocytes, the uptake of glutamate in synaptic cleft is reduced, further enhancing excitotoxicity.
Decreased renal clearance rate: When renal dysfunction occurs, the concentration of Meropenem cerebrospinal fluid increases (AUC ₀ - ∞ increases by 2.3 times), significantly increasing the risk of epilepsy.
The immune mechanism of allergic reactions
IgE mediated type I hypersensitivity reaction: Drugs act as haptens and bind to carrier proteins, inducing specific IgE production. Upon further contact, it triggers degranulation of mast cells and releases mediators such as histamine.
Type IV hypersensitivity reaction mediated by T cells: Drug specific T cell activation releases cytokines (such as IFN - γ, TNF - α), leading to delayed type hypersensitivity reaction or DRESS syndrome in the skin.
Risk factors and high-risk populations
Patient related factors
Renal insufficiency: When CrCL<50mL/min, the half-life of Meropenem Tablets is prolonged (from 1 hour to 4-6 hours), cerebrospinal fluid concentration increases, and the risk of epilepsy increases.
History of CNS: Patients with a history of traumatic brain injury, brain tumors, or epilepsy have a reduced threshold for epilepsy and an incidence 3-5 times higher than the general population.
Allergic constitution: Individuals with a history of allergy to penicillin or cephalosporins have a 2-4 fold increased risk of allergic reactions.
Elderly patients (>65 years old): liver and kidney function decline, drug clearance rate decreases, and the incidence of adverse reactions is 1.5 times higher than that of younger patients.
Drug related factors
Dosage and treatment duration: When the dose is greater than 2g/day, the risk of epilepsy increases by 1.8 times; When the course of treatment exceeds 14 days, the incidence of liver toxicity increases from 0.3% to 1.2%.
Administration method: Rapid intravenous infusion (<5 minutes) can cause a sudden increase in blood drug concentration, and the risk of epilepsy is 2.3 times higher than intravenous infusion (30 minutes).
Combination therapy: When used in combination with valproic acid, the AUC of valproic acid decreases by 50% -70%, and the risk of epileptic seizures increases by 5-8 times; Combined use with nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of gastrointestinal bleeding by 1.5 times.
Preventive measures
Dose adjustment: CrCL 26-50mL/min：1g q12h; CrCL 10-25mL/min：0.5g q12h; CrCL <10mL/min：0.5g q24h.
Optimization of administration method: Extending the intravenous infusion time to more than 30 minutes reduces the peak blood drug concentration (Cmax); Avoid simultaneous use with valproic acid. If combined use is necessary, monitor the blood concentration of valproic acid (target value 50-100 μ g/mL).
High risk population screening: Inquire about CNS medical history, allergy history, and renal function before medication; Monitor ALT/AST and bilirubin levels in elderly patients or those with liver dysfunction.
Monitoring and early identification
Neurological monitoring: Daily assessment of consciousness status, muscle tone, and premonitory seizures (such as numbness of the lips and visual abnormalities) during medication;
Monitor electroencephalogram (EEG) changes in patients with renal insufficiency.
Gastrointestinal monitoring: Record the frequency and characteristics of bowel movements daily for the first 3 days after medication, and be alert to the formation of bloody stools or pseudomembranes;
Monitor fecal occult blood when using NSAIDs in combination.
Skin monitoring: Check the skin daily after medication, with a focus on the trunk and flexed limbs;
When redness or blisters appear, stop taking the medication immediately and take the skin lesion tissue for pathological examination.
Treatment measures
Seizures: Immediately stop taking the medication and keep the respiratory tract unobstructed; Intravenous injection of diazepam 5-10mg, followed by a loading dose of phenytoin sodium 15-20mg/kg; For patients with renal insufficiency, priority should be given to levetiracetam (without dose adjustment).
Antibiotic associated diarrhea: Mild symptoms: Oral probiotics (such as Saccharomyces boulardii) and montmorillonite powder; Severe: Take oral vancomycin 125mg q6h or metronidazole 500mg q8h for 10-14 days.
Allergic reactions: Mild: Discontinue medication and take oral antihistamines (such as cetirizine 10mg/day); Severe: Stop medication immediately, subcutaneous injection of adrenaline 0.3-0.5mg, followed by corticosteroids (such as methylprednisolone 40-80mg ivgtt).
Management of special populations
Pregnancy and lactation period
Pregnancy period: FDA classification B, but animal experiments have shown that high doses (>1000mg/kg) can cause embryotoxicity. Use with caution in the middle and late stages of pregnancy.
Breastfeeding period: Medication can be secreted into breast milk (with a concentration about 0.5 times that of maternal blood), and breastfeeding should be suspended or artificial feeding should be chosen during the medication period.
Children
Dose adjustment:
Age ≥ 3 months: 20mg/kg q8h (maximum dose 1g/time);
<3 months old: 20mg/kg q12h (due to low renal maturity and prolonged half-life).
Epilepsy monitoring:
Continuous EEG monitoring for the first 72 hours after medication in children with meningitis to alert for subclinical epileptic seizures.
Renal insufficiency
Hemodialysis patients:
After dialysis, supplement with a dose of 250-500mg to maintain a blood drug concentration of>4 μ g/mL;
Continuous renal replacement therapy (CRRT):
Adjust the dosage according to the filter type (e.g. 1g q12h is required for CVVHDF).
Frequently Asked Questions
Is there a pill form of meropenem?
+
-
Meropenem is used to treat various infections, especially from drug-resistant bacteria. Meropenem administration demands specialized resources and trained nurses. Meropenem is only available as an injectable formulation due to its poor chemical stability and permeability across the gut.
Is meropenem given IV or oral?
+
-
Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3 and 6.6). Alternatively, doses up to 1 g can be given as an intravenous bolus injection over approximately 5 minutes.
Is tab meropenem a strong antibiotic?
+
-
Is Meropenem a Strong Antibiotic? Meropenem is the strongest antibiotic after vancomycin. Meropenem (Merrem, Meronem) is an antibacterial specialist of the carbapenem family with a wide scope of use. It has proven to be the definitive course of treatment before the causative organism has been identified.
Hot Tags: meropenem tablets, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale